- Home
- NUWE vs PPCB Comparison
NUWE vs PPCB Comparison
Compare NUWE & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUWE | PPCB |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | Australia |
| Employees | 38 | 2 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NUWE | PPCB |
|---|---|---|
| Price | $1.17 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 6.3M |
| Earning Date | 05-05-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.14 | N/A |
| Revenue Next Year | $18.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.10 |
| 52 Week High | $25.95 | $10.69 |
Technical Indicators
Market Signals| Indicator | NUWE | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 40.64 |
| Support Level | $0.96 | N/A |
| Resistance Level | $1.19 | $0.13 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 14.29 | 10.72 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.